Mizuho Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $179.00

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target lifted by Mizuho from $145.00 to $179.00 in a research report sent to investors on Friday morning, Benzinga reports. Mizuho currently has a buy rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. UBS Group raised their price […]

Related Keywords

Canada , New Jersey , United States , Sarepta , Stephen Mayo , Royal Bank , Sarepta Therapeutics Company Profile , Sarepta Therapeutics Inc , Securities Exchange Commission , Vanguard Group Inc , Investment Management , Capula Management Ltd , Citigroup , Jersey Common Pension Fund , Sarepta Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Stephen Mayo , Exchange Commission , Director Kathryn Jean Boor , Mahoney Asset Management , Management Ltd , Sarepta Therapeutics Daily ,